USP Drug Class Alternatives Include FEHBP, American Hospital System, CMS Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Medicare drug plans that choose not to follow the U.S. Pharmacopeia's model formulary drug classes will have their formularies compared to other classification systems, the Centers for Medicare & Medicaid Services' draft Medicare formulary review guidelines state
You may also be interested in...
USP Names “Key” Drug Types, But Leaves Them Out Of Formulary Guidelines
The U.S. Pharmacopeia is dropping recommended drug class subdivisions from its model guidelines in favor of providing CMS with a list of "formulary key drug types" the agency should consider in reviewing plans for the Medicare Rx program
USP Names “Key” Drug Types, But Leaves Them Out Of Formulary Guidelines
The U.S. Pharmacopeia is dropping recommended drug class subdivisions from its model guidelines in favor of providing CMS with a list of "formulary key drug types" the agency should consider in reviewing plans for the Medicare Rx program
Medicare Formulary Review Should Avoid Comparisons To Medicaid Lists, AMCP Says
The Academy of Managed Care Pharmacy's comments on CMS' formulary review guidelines say some Medicaid preferred drug lists are based on cost, rather than medical appropriateness. Using cost-based PDLs as benchmarks will undermine evidence-based formularies, the group says.